Volumetric and diffusion MRI abnormalities associated with dysarthria in multiple sclerosis.

diffusion MRI dysarthria multiple sclerosis neurolinguistics

Journal

Brain communications
ISSN: 2632-1297
Titre abrégé: Brain Commun
Pays: England
ID NLM: 101755125

Informations de publication

Date de publication:
2024
Historique:
received: 06 12 2023
revised: 16 04 2024
accepted: 21 05 2024
medline: 7 6 2024
pubmed: 7 6 2024
entrez: 7 6 2024
Statut: epublish

Résumé

Up to half of all people with multiple sclerosis experience communication difficulties due to dysarthria, a disorder that impacts the motor aspects of speech production. Dysarthria in multiple sclerosis is linked to cerebellar dysfunction, disease severity and lesion load, but the neuroanatomical substrates of these symptoms remain unclear. In this study, 52 participants with multiple sclerosis and 14 age- and sex-matched healthy controls underwent structural and diffusion MRI, clinical assessment of disease severity and cerebellar dysfunction and a battery of motor speech tasks. Assessments of regional brain volume and white matter integrity, and their relationships with clinical and speech measures, were undertaken. White matter tracts of interest included the interhemispheric sensorimotor tract, cerebello-thalamo-cortical tract and arcuate fasciculus, based on their roles in motor and speech behaviours. Volumetric analyses were targeted to Broca's area, Wernicke's area, the corpus callosum, thalamus and cerebellum. Our results indicated that multiple sclerosis participants scored worse on all motor speech tasks. Fixel-based diffusion MRI analyses showed significant evidence of white matter tract atrophy in each tract of interest. Correlational analyses further indicated that higher speech naturalness-a perceptual measure of dysarthria-and lower reading rate were associated with axonal damage in the interhemispheric sensorimotor tract and left arcuate fasciculus in people with multiple sclerosis. Axonal damage in all tracts of interest also correlated with clinical scales sensitive to cerebellar dysfunction. Participants with multiple sclerosis had lower volumes of the thalamus and corpus callosum compared with controls, although no brain volumetrics correlated with measures of dysarthria. These findings indicate that axonal damage, particularly when measured using diffusion metrics, underpin dysarthria in multiple sclerosis.

Identifiants

pubmed: 38846538
doi: 10.1093/braincomms/fcae177
pii: fcae177
pmc: PMC11154149
doi:

Types de publication

Journal Article

Langues

eng

Pagination

fcae177

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the Guarantors of Brain.

Déclaration de conflit d'intérêts

K.H.K., F.M.C.B., M.S. and A.M. have nothing to disclose. A.v.d.W. served on advisory boards and receives unrestricted research grants from Novartis, Biogen, Merck and Roche; has received speaker’s honoraria and travel support from Novartis, Roche and Merck; and receives grant support from the National Health and Medical Research Council of Australia and MS Research Australia. A.P.V. is the chief science officer of Redenlab Inc. G.N. works in the scientific development for Redenlab Inc. S.K. received unrestricted research grants from Biogen and grant support from MS Research Australia. I.H.H receives grants from the National Health and Medical Research Council and honoraria from Steminent Biotherapeutics and PTC therapeutics.

Auteurs

Katherine H Kenyon (KH)

Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC 3004, Australia.
Centre for Neuroscience of Speech, University of Melbourne, Parkville, VIC 3052, Australia.

Myrte Strik (M)

Spinoza Centre for Neuroimaging, Netherlands Institute for Neuroscience, Royal Academy for Arts and Sciences, KNAW, Amsterdam 1105 BK, The Netherlands.
Melbourne Brain Centre Imaging Unit, Department of Radiology, University of Melbourne, Parkville, VIC 3052, Australia.

Gustavo Noffs (G)

Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC 3004, Australia.
Centre for Neuroscience of Speech, University of Melbourne, Parkville, VIC 3052, Australia.
Department of Neurology, Royal Melbourne Hospital, Parkville, VIC 3052, Australia.
Redenlab Inc, Melbourne, VIC 3000, Australia.

Angela Morgan (A)

Murdoch Children's Research Institute, Genomic Medicine, Speech and Language Group, Parkville 3052, Australia.
Department of Speech Pathology and Audiology, University of Melbourne, Parkville 3052, Australia.

Scott Kolbe (S)

Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC 3004, Australia.

Ian H Harding (IH)

Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC 3004, Australia.

Adam P Vogel (AP)

Centre for Neuroscience of Speech, University of Melbourne, Parkville, VIC 3052, Australia.
Melbourne Brain Centre Imaging Unit, Department of Radiology, University of Melbourne, Parkville, VIC 3052, Australia.
Redenlab Inc, Melbourne, VIC 3000, Australia.
Division of Translational Genomics of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen 72076, Germany.
Center for Neurology, University Hospital Tübingen, Tübingen 72076, Germany.
The Bionics Institute, East Melbourne, VIC 3002, Australia.

Frederique M C Boonstra (FMC)

Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC 3004, Australia.

Anneke van der Walt (A)

Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC 3004, Australia.
Spinoza Centre for Neuroimaging, Netherlands Institute for Neuroscience, Royal Academy for Arts and Sciences, KNAW, Amsterdam 1105 BK, The Netherlands.
The Bionics Institute, East Melbourne, VIC 3002, Australia.

Classifications MeSH